<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288625</url>
  </required_header>
  <id_info>
    <org_study_id>SUN-2011-DP</org_study_id>
    <nct_id>NCT01288625</nct_id>
  </id_info>
  <brief_title>Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine</brief_title>
  <official_title>Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence of stomatitis when treating with
      amifostine before radiation treatment.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    There were IP availability issues due to which the study could not be started.
  </why_stopped>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and duration of oral mucositis</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Oral Mucositis</condition>
  <condition>Stomatitis</condition>
  <arm_group>
    <arm_group_label>Cytofos group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amifostine 500 mg sc, qod, 3 times per week Radiation treatment 30 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytofos group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amifostine 500mg rinsing wash, qod, 3 times per week Radiation treatment 5 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation treatment 1.8-2.0 Gy/day × 30-35 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifostine</intervention_name>
    <description>500 mg sc, qod, 3 times per week</description>
    <arm_group_label>Cytofos group A</arm_group_label>
    <arm_group_label>Cytofos group B</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Amifostine</intervention_name>
    <description>500mg rinsing wash, qod, 3 times per week</description>
    <arm_group_label>Cytofos group A</arm_group_label>
    <arm_group_label>Cytofos group B</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-70 years old, male or female

          2. Primary treatment of phase I-IVA head and neck cancer patients, identified by
             histological and pathological diagnosis

          3. Postoperative patients should receive radiation treatment in 12 weeks

          4. ECOG &lt;2

          5. Expected lifetime ≥6months

          6. No severe complications (hypertension, CHD, diabetes and psychiatric history, etc.)

          7. Not involved in other clinical trials

          8. Sign ICF

        Exclusion Criteria:

          1. ECOG &gt;2

          2. Suffered other cancers in the past 5 years

          3. Received amifostine treatment in the past 4 weeks

          4. Unable to complete treatment or sign ICF because of medical or physical reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang ge</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Institute of Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>October 12, 2012</last_update_submitted>
  <last_update_submitted_qc>October 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Identify whether Cytofos can reduce the incidence and duration of HNC patients' oral mucositis caused by radiotherapy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

